Why the study?
Does acetazolamide cause weakness in patients with paramyotonia congenita?
Does acetazolamide cause weakness in patients with paramyotonia congenita?
Acetazolamide may be deleterious in patients with paramyotonia congenita, as it can induce severe quadriparesis despite improving myotonia.
Acetazolamide may induce quadriparesis in paramyotonia congenita despite myotonia relief; single case leaves safety questions open.
Acetazolamide has been shown to be effective prophylaxis for both hypokalemic and hyperkalemic paralysis. A patient with paramyotonia congenita, a related disorder with myotonia and episodic weakness, was studied during treatment with acetazolamide. Athough the patient's myotonia was virtually abolished, severe quadriparesis was produced during each trial of acetazolamide. This response distinguished this patient's condition from other forms of familial periodic paralysis and suggests that acetazolamide may be deleterious to some patients with periodic paralysis.
No takes yet. Share an insight, caveat, or question.
Jack E. Riggs (1977) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: